EGFR-Mutant Lung Cancer Clinical Trial
Official title:
A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
| Verified date | November 2018 |
| Source | Memorial Sloan Kettering Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to test the safety of different ways of taking erlotinib. The
investigators want to find out what effects, good and/or bad, combination daily low dose and
twice weekly high dose erlotinib has on the patient and lung cancer. The investigators are
also seeing whether different schedules of erlotinib are better at treating lung cancer that
has spread to the central nervous system.
CNS expansion phase:
The pulse continuous regimen will be then assess in patients with EGFR mutant lung cancers
and CNS involvement. An additional expansion cohort (A) will enroll 19 patients with newly
diagnosed EGFR mutant lung cancer with CNS involvement at diagnosis. The patients in the
expansion cohorts will undergo the same treatment plan as the patients in the dose expansion
cohort. A patient in the expansion cohorts will not be replaced if he/she does not finish the
first 28 day (cycle 1) treatment period.
| Status | Completed |
| Enrollment | 53 |
| Est. completion date | November 8, 2018 |
| Est. primary completion date | November 8, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - MSKCC pathologically-proven diagnosis locally advanced Stage III not amenable to definitive, curative treatment or Stage IV or recurrent non-small cell lung cancer - Documented presence of EGFR mutation confirmed by MSKCC or a local facility. - No prior treatment with erlotinib, gefitinib, or other EGFR tyrosine kinase inhibitors - Age = 18 years - Measurable (RECIST 1.1) indicator lesion not previously irradiated. - Karnofsky Performance Status = 70% - Ability to take oral medications - A negative serum pregnancy test obtained within 4 weeks prior to the start of treatment in all women of child-bearing potential. - All women of child bearing potential and sexually active men must agree to use adequate methods of birth control throughout the study which includes use of oral contraceptives with an additional barrier methods, double barrier methods, Depo-Provera, permanent sterilization of patient or partner or total abstinence. Expansion A: - brain metastases or leptomeningeal not previously treated with radiation or surgery Exclusion Criteria: - Inadequate recovery from any toxicity related to prior treatment (to Grade 2 or baseline). - Inadequate hematologic function defined as ANC < 1000 cells/mm³, Platelet count <75,000/mm³ or Hemoglobin <9.0g/dL. - Inadequate hepatic function defined by AST/ALT >3x upper limit of normal (ULN), Total bilirubin>2x ULN, Alkaline phosphatase >3x ULN. - Symptomatic brain metastasis requiring radiation therapy or escalating doses of steroids. - Patients with clinically stable brain metastases or leptomeningeal disease (previously treated or untreated) are eligible. Patients in expansion cohort A must have at least one untreated CNS lesion - Women who are breastfeeding or pregnant. - Any evidence of clinically active interstitial lung disease. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Memoral Sloan Kettering Cancer Center | Basking Ridge | New Jersey |
| United States | Memorial Sloan Kettering Commack | Commack | New York |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| United States | Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York |
| United States | Memoral Sloan Kettering Cancer Center at Phelps | Sleepy Hollow | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Memorial Sloan Kettering Cancer Center | Astellas Pharma US, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | to determine the maximum tolerated dose (MTD) | The study will use a standard 3+3 dose escalation design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made. | 1 year | |
| Secondary | to evaluate the safety profile | Toxicity will be graded according to NCI CTCAE, version 4.0. The analysis of safety/tolerability data will be descriptive; toxicity events will be individually tabulated. | 1 year | |
| Secondary | Progression Free Survival (PFS) | Progression free survival (PFS) is defined as the duration of time from first treatment to time of progression or death, whichever occurs first. | 1 year | |
| Secondary | Response rate (RR) | sum of complete responses and partial responses according to RECIST 1.1 | 1 year | |
| Secondary | Overall survival (OS) | Overall survival (OS) is defined as the duration of time from first treatment to time of death. | 1 year |